Key result
June 2025 update summarizes recent advances in HF management and therapies.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
Timely HF update for clinicians; leaves open validation of new therapies in prospective trials.
inhibitor; CV, cardiovascular; EJHF, European Journal of Heart Failure; ESKD, end-stage kidney disease; HF, heart failure; HFA, Heart Failure Association; HFH, heart failure hospitalization; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HSS, hypertonic saline solution; IPD, individual participant data; IV, intravenous; LA, left atrial; MR-proADM, mid-regional pro-adrenomedullin; Na, sodium; NP, natriuretic peptide; PAP, pulmonary artery pressure; QoL, quality of life; SGLT2i, sodium–glucose cotransporter 2 inhibitor.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2025) studied this question. Recent developments in heart failure management and therapies are summarized in this June 2025 update.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: